Your search history is turned on.
Date: April 15, 2024 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES CANNTAB THERAPEUTICS LIMITED OBTAINS PARTIAL REVOCATION ORDER Toronto, ON April 15, 2024 Canntab Therapeutics Limited (the "Corporation") is pleased to announce that it intends to complete a private placement to raise up to $100,000 by way of an offering of up to 16,666,6...
Date: September 28, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Avicanna - MCR re MCTO FORM 51-102F3 MATERIAL CHANGE REPORT Item 1. Name and Address of Company Canntab Therapeutics Limited (the Company) 1 Adelaide Street East, Suite 801 Toronto, Ontario M5C 2V9 Item 2. Date of Material Change September 18, 2023. Item 3. News Release A news release was disseminated on September 18, 2023, via...
Date: September 18, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
CANNTAB THERAPEUTICS LIMITED PROVIDES UPDATE ON APPLICATION FOR MANAGEMENT CEASE TRADE ORDER Toronto, ON September 18, 2023 Canntab Therapeutics Limited (CSE:PILL)(OTCQB:CTABF)(FRA:TBF1) (the "Corporation") announces that the Ontario Securities Commission (the OSC) has rejected the Corporations application for a management cease ...
Date: January 26, 2023 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Microsoft Word - Form 52109FV2 CFO re IFS FINAL Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Richard Goldstein, the Chief Financial Officer of Canntab Therapeutics Limited (the Issuer), certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the Interim F...
Microsoft Word - Form 52109FV2 CEO re IFS FINAL Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Richard Goldstein, the Interim Chief Executive Officer of Canntab Therapeutics Limited (the Issuer), certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the In...
CannTher 2022Nov30 MD&A (Final).pdf CANNTAB THERAPEUTICS LIMITED MANAGEMENT DISCUSSION AND ANALYSIS SIX MONTHS ENDED NOVEMBER 30, 2022 AND 2021 CANNTAB THERAPEUTICS LIMITED MANAGEMENT DISCUSSION AND ANALYSIS SIX MONTHS ENDED NOVEMBER 30, 2022 AND 2021 The following management discussion and analysis ("MD&A") of Canntab Therapeutics Limited ("Canntab" or "the Comp...
CannTher 2022Nov30 FS (Final).pdf CANNTAB THERAPEUTICS LIMITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS THREE AND SIX MONTHS ENDED NOVEMBER 30, 2022 AND 2021 (Stated in $CAD) (Unaudited - Prepared by Management) NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS The accompanying unaudited interim condensed consolidated financial statements of the C...
Date: November 25, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
Microsoft Word - MCR re PR re Corporate Update FINAL FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company Canntab Therapeutics Limited (Canntab) 223 Riviera Drive Markham, Ontario, L3R 5J6 Item 2: Date of Material Change November 17, 2022. Item 3: News Release A news release with respect to the material change refer...
Date: November 22, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario
CANNTAB ANNOUNCES CORPORATE UPDATE Toronto, Ontario, November 22, 2022 - Canntab Therapeutics Limited (CSE: PILL) (OTCQB: CTABF) (FRA: TBF1) (the Company or Canntab) a leading innovator in cannabinoid and terpene blends in hard pill form for therapeutic applications, is providing an update on several matters impacting the Company. Over the past nu...
Date: October 28, 2022 Jurisdictions: Alberta, British Columbia, Manitoba, Ontario